NASDAQ:VERU - Veru Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $35.40
  • Forecasted Upside: 150.71 %
  • Number of Analysts: 5
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 5 Buy Ratings
  • 0 Strong Buy Ratings
$14.12
▲ +0.74 (5.53%)

This chart shows the closing price for VERU by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Veru Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VERU and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VERU

Analyst Price Target is $35.40
▲ +150.71% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Veru in the last 3 months. The average price target is $35.40, with a high forecast of $0.00 and a low forecast of $0.00. The average price target represents a 150.71% upside from the last price of $14.12.

This chart shows the closing price for VERU for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 5 investment analysts is to buy stock in Veru. This Buy consensus rating has held steady for over two years.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/29/2020
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/27/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/28/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
8/26/2021
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
11/24/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
2/22/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/23/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
5/23/2022

Latest Recommendations

  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/18/2022Brookline Capital AcquisitionBoost Price TargetBuy ➝ Buy$29.00 ➝ $31.00Medium
5/18/2022Brookline Capital ManagementBoost Price TargetBuy ➝ Buy$29.00 ➝ $31.00Medium
5/13/2022Cantor FitzgeraldReiterated RatingOverweightHigh
5/13/2022Jefferies Financial GroupBoost Price Target$33.00 ➝ $55.00High
4/12/2022OppenheimerBoost Price TargetOutperform$25.00 ➝ $36.00High
4/12/2022HC WainwrightBoost Price TargetBuy$21.00 ➝ $24.00High
1/11/2022HC WainwrightReiterated RatingBuy$21.00High
12/3/2021HC WainwrightReiterated RatingBuy$20.00High
10/14/2021HC WainwrightReiterated RatingBuy$21.00High
9/21/2021HC WainwrightReiterated RatingBuy$21.00Low
8/27/2021Brookline Capital ManagementReiterated RatingBuyMedium
8/27/2021OppenheimerReiterated RatingBuy$26.00High
6/28/2021HC WainwrightReiterated RatingBuy$21.00High
4/13/2021Jefferies Financial GroupInitiated CoverageBuy$19.00High
2/25/2021HC WainwrightLower Price TargetBuy$22.00 ➝ $21.00High
2/11/2021OppenheimerBoost Price Target$19.00 ➝ $24.00Low
2/9/2021HC WainwrightBoost Price TargetBuy$12.00 ➝ $17.00Low
12/16/2020OppenheimerBoost Price TargetOutperform$9.00 ➝ $19.00Low
12/14/2020Brookline Capital ManagementBoost Price Target$13.00 ➝ $17.00High
12/14/2020Cantor FitzgeraldBoost Price TargetOverweight$6.00 ➝ $15.00High
12/10/2020HC WainwrightBoost Price TargetBuy$6.00 ➝ $8.00High
9/21/2020OppenheimerReiterated RatingBuy$9.00High
8/14/2020Brookline Capital ManagementReiterated RatingBuyLow
8/14/2020OppenheimerReiterated RatingBuy$9.00High
6/22/2020HC WainwrightReiterated RatingBuy$6.00High
5/14/2020OppenheimerBoost Price TargetOutperform$9.00Medium
5/6/2020HC WainwrightReiterated RatingBuy$6.00Low
1/21/2020HC WainwrightReiterated RatingBuy ➝ Buy$4.50 ➝ $6.00High
12/13/2019HC WainwrightReiterated RatingBuy$4.50High
10/3/2019HC WainwrightReiterated RatingBuyLow
8/9/2019HC WainwrightReiterated RatingBuy$4.50High
7/29/2019Brookline Capital ManagementInitiated CoverageBuy$12.00High
7/1/2019Cantor FitzgeraldInitiated CoverageOverweight$6.00High
6/27/2019HC WainwrightReiterated RatingBuy$4.50Medium
6/5/2019HC WainwrightSet Price TargetBuy$5.00Medium
3/20/2019CIBCInitiated CoverageOutperform ➝ Outperform$5.00High
3/19/2019OppenheimerInitiated CoverageOutperform$5.00 ➝ $5.00High
2/14/2019Maxim GroupSet Price TargetBuy$6.00Medium
1/23/2019HC WainwrightReiterated RatingBuy$4.50Low
12/14/2018HC WainwrightSet Price TargetBuy$5.00Low
9/13/2018HC WainwrightSet Price TargetBuy$5.00Medium
8/28/2018HC WainwrightSet Price TargetBuy$5.00Low
8/27/2018Maxim GroupReiterated RatingBuy$10.00High
8/15/2018HC WainwrightReiterated RatingBuy$5.00Medium
8/14/2018Maxim GroupReiterated RatingBuy$10.00Low
7/3/2018Maxim GroupInitiated CoverageBuyHigh
6/25/2018Dawson JamesReiterated RatingBuyMedium
5/18/2018HC WainwrightSet Price TargetBuy$5.00Low
5/10/2018HC WainwrightSet Price TargetBuy$5.00Low
3/23/2018HC WainwrightSet Price TargetBuy$5.00High
3/6/2018HC WainwrightSet Price TargetBuy$5.00High
2/15/2018HC WainwrightSet Price TargetBuy$5.00Low
1/9/2018HC WainwrightSet Price TargetBuy$5.00N/A
1/3/2018HC WainwrightSet Price TargetBuy$5.00High
12/14/2017HC WainwrightSet Price TargetBuy$5.00High
11/14/2017HC WainwrightSet Price TargetBuy$5.00N/A
10/4/2017HC WainwrightReiterated RatingBuy$5.00Low
7/26/2017HC WainwrightSet Price TargetBuy$5.00High
7/26/2017Rodman & RenshawInitiated CoverageBuy ➝ Buy$5.00High
(Data available from 5/24/2017 forward)

News Sentiment Rating

0.34 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 4 positive mentions
  • 1 negative mentions
  • 1 very negative mentions
10/26/2021
  • 0 very positive mentions
  • 10 positive mentions
  • 1 negative mentions
  • 4 very negative mentions
11/25/2021
  • 5 very positive mentions
  • 23 positive mentions
  • 3 negative mentions
  • 2 very negative mentions
12/25/2021
  • 0 very positive mentions
  • 12 positive mentions
  • 3 negative mentions
  • 3 very negative mentions
1/24/2022
  • 3 very positive mentions
  • 19 positive mentions
  • 10 negative mentions
  • 8 very negative mentions
2/23/2022
  • 1 very positive mentions
  • 3 positive mentions
  • 5 negative mentions
  • 1 very negative mentions
3/25/2022
  • 9 very positive mentions
  • 22 positive mentions
  • 7 negative mentions
  • 0 very negative mentions
4/24/2022
  • 16 very positive mentions
  • 41 positive mentions
  • 4 negative mentions
  • 5 very negative mentions
5/24/2022

Current Sentiment

  • 16 very positive mentions
  • 41 positive mentions
  • 4 negative mentions
  • 5 very negative mentions

Recent Stories by Sentiment

Veru logo
Veru Inc., an oncology biopharmaceutical company, focuses on developing medicines for the management of cancers. Its commercial products comprise FC2 female condom/internal condom for the dual protection against unintended pregnancy and the transmission of sexually transmitted infections for ministries of health, government health agencies, U.N. agencies, nonprofit organizations, and commercial partners. The company's development drug candidates include Enobosarm, an oral selective androgen receptor agonist that is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Sabizabulin, which is phase IIb clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; Enobosarm + abemaciclib combination therapy, which is in phase III clinical trial for the treatment of AR+ ER+ HER2- metastatic breast cancer; and Sabizabulin + enobosarm combination therapy, an oral targeted cytoskeleton disruptor plus selective androgen receptor agonist, which is in phase II clinical trial for the treatment of metastatic triple negative breast cancer. Its drug candidates also comprise Sabizabulin, which is in Phase II clinical trial for the treatment of metastatic castration and androgen receptor targeting agent resistant prostate cancer; VERU-100, a GnRH antagonist peptide injection, which is in Phase II clinical trial for the treatment of advanced hormone sensitive prostate cancer; Zuclomiphene Citrate, which is in Phase II clinical trial for treating hot flashes; and Sabizabulin, which is in phase III clinical trial for the treatment of SARS-CoV-2 in subjects at high risk for acute respiratory distress syndrome. In addition, the company is advancing a new drug formulation for the treatment of men with lower urinary tract symptoms from an enlarged prostate. The company was formerly known as The Female Health Company and changed its name to Veru Inc. in July 2017. Veru Inc. was incorporated in 1971 and is headquartered in Miami, Florida.
Read More

Today's Range

Now: $14.12
Low: $12.35
High: $14.21

50 Day Range

MA: $9.27
Low: $4.35
High: $15.60

52 Week Range

Now: $14.12
Low: $4.34
High: $17.50

Volume

8,125,900 shs

Average Volume

15,157,697 shs

Market Capitalization

$1.13 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Veru?

The following Wall Street sell-side analysts have issued research reports on Veru in the last twelve months: Brookline Capital Acquisition Corp., Brookline Capital Management, Cantor Fitzgerald, HC Wainwright, Jefferies Financial Group Inc., Oppenheimer Holdings Inc., TheStreet, and Zacks Investment Research.
View the latest analyst ratings for VERU.

What is the current price target for Veru?

0 Wall Street analysts have set twelve-month price targets for Veru in the last year. Their average twelve-month price target is $35.40, suggesting a possible upside of 150.7%.
View the latest price targets for VERU.

What is the current consensus analyst rating for Veru?

Veru currently has 5 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VERU will outperform the market and that investors should add to their positions of Veru.
View the latest ratings for VERU.

How do I contact Veru's investor relations team?

Veru's physical mailing address is 48 NW 25th Street Suite 102, Miami FL, 33127. The company's listed phone number is (305) 509-6897 and its investor relations email address is [email protected] The official website for Veru is www.veruhealthcare.com. Learn More about contacing Veru investor relations.